°®¶¹´«Ã½

Bootcamp: Workshop 1 | Discovery Strategies

• Mining Natural Resources
  Speaker: Rolf Müller, HIPS, Germany.


• Antibiotic Discovery Strategies: New Targets, Old Targets, No Targets
  Speaker: Alice Erwin, Consultant, U.S.


• Machine Learning and Chemogenomics to Improve Early Antibiotic Discovery
  Speaker: Silvia T. Cardona, University of Manitoba, Canada.


• 3–3:15 p.m. | Panel Discussion.

Coffee Break

Bootcamp: Workshop 2 | Challenges of Antibacterial Drug Discovery

• Combined Diagnostic-Therapeutic Discovery Strategies (Theranostics)
  Speaker: Robin Patel, Mayo Clinic, U.S.


• Animal Models, In Vitro Models: An Experimental Perspective
  Speaker: Lynn Miesel, Pharmacology Discovery Services, U.S.


• Pitfalls in the Discovery and Non-Clinical Development of Alternative Antibacterial Therapies
  Speaker: Peter Warn, Magic Bullet Consulting, U.K.


• 5:15–5:30 p.m. | Panel Discussion.

Welcome Reception

Continental Breakfast

Opening Remarks

Keynote Speaker

Session 1: The Impact of Different Approaches to Breakpoints

• 9:15–9:45 a.m. | Differences in Approach Between CLSI, EUCAST and USCAST
  Speaker: Gunnar Kahlemeter, The European Committee on Antimicrobial Susceptibility Testing (EUCAST), Sweden.


• 9:45–10:15 a.m. | Impact of Different Testing Methodologies on Clinical Development
  Speaker: Jane E. Ambler, ContraFect, U.S.


• 10:15–10:45 a.m. | Coffee Break.


• 10:45–11:15 a.m. | Impact of Different Breakpoints on Clinical Trials
  Speaker: Angela Talley, Scientific and Medical Affairs Consulting, U.S.


• 11:15–11:45 a.m. | Session 1 Panel Discussion and Wrap-Up.

Lunch

Session 2: Are We Developing the Right New Antibacterials?

• 12:45–1:15 p.m. | Overview of AB in Development and Prioritized Paediatric Formulation & Indication for Children and Neonate (PADO exercise)
  Speaker: Valeria Gigante, World Health Organization (WHO), Switzerland.


• 1:15–1:45 p.m. | Access to New Antibacterials to Address Global Public Health Needs
  Speaker: Jennifer Cohn, Global Antibiotic Research & Development Partnership (GARDP), Switzerland.


• 1:45–2:15 p.m. | Are We Addressing the Needs of Children, Infants and Neonates?
  Speaker: Andrew Whitelaw, Stellenbosch University, South Africa.


• 2:15–2:45 p.m. | Global Strategies for New Products
  Speaker: Gareth Morgan, Shionogi, U.S.


• 2:45–3:15 p.m. | Session 2 Panel Discussion and Wrap-Up.

Rapid Fire Oral Presentations Session 1

Coffee Break

Poster Presentations Session 1

Young Investigators Presentations I

• 4:30–5 p.m.| How Useful is the Current Antibiotic Pipeline Going to Be in India?
  Speaker: Yamuna Devi Bakthavatchalam, Christian Medical College & Hospital, Vellore, India. Pre-recorded talk.


• 5–5:30 p.m.| ARLG DOOR Work in cUTI, HABP/VABP and ABSSSI
  Speaker: Jessica Renee Howard-Anderson, Emory University School of Medicine, U.S.

Continental Breakfast

Session 3: Antifungal Drug Development

• 8–8:30 a.m. | Unmet Need/Pipeline Update for Antifungal Medications
  Speaker: Kieran Marr, Johns Hopkins University, U.S.


• 8:30–10 a.m. | Complexities of Antifungal and Antibacterial Clinical Programs: Indications vs. Organisms
  Speaker: Kieran Marr, Johns Hopkins University, U.S.
• 8:30–9 a.m. | Isavuconazole, Speaker: Laura Kovanda, Astellas Pharma Inc., U.S.
• 9–9:30 a.m. | Olorofim, Speaker: John Rex, F2G, U.S.
• 9:30–10 a.m. | Overview of Specific Organism Antibacterial Trials, Keith Rodvold, University of Illinois, U.S.


• 10–10:30 a.m. | Coffee Break


• 10:30–11 a.m. | Session 3 Panel Discussion and Wrap-Up: Are There Aspects of Antifungal Regulatory Pathway That Could Be Applied to Antibacterials?
  Kieran Marr, Johns Hopkins University, U.S.
  
  Additional panel members: Cornelius “Neil” Clancy, University of Pittsburgh, U.S., Peter Kim, FDA, U.S., Peter Pappas, University of Alabama, U.S.

Rapid Fire Oral Presentations Session 2

Poster Presentations Session 2

Lunch

Session 4: Updates in Antibiotic Stewardship

• 1:15–1:45 p.m. | Day in the Life of an Antimicrobial Steward: An Overview of Stewardship Program Operations
  Speaker: Alicia Demirjian, U.K. Health Security Agency (UKHSA), U.K.


• 1:45–2:15 p.m. | Technological Tools for Antimicrobial Stewardship
  Speaker: Josh Herigon, Children’s Mercy Hospital, U.S.


• 2:15–2:45 p.m. | Patient-Specific Clinical Decision Support Through PK-PD Optimization
  Speaker: Christopher Rubino, Institute for Clinical Pharmacodynamics, U.S.


• 2:45–3:15 p.m. | Evidence Behind Shorter Duration of Antibiotics Treatments
  Speaker: Rebecca Same, Children's Hospital of Philadelphia, U.S.


• 3:15–3:45 p.m. | Session 4 Panel Discussion and Wrap-Up.

Coffee Break

Young Investigators Presentations

• 4:15–4:45 p.m. | Access to Antifungals in LMIC
  Speaker: Katherine Stott, University of Liverpool, U.K.


• 4:45–5:15 p.m. | The development of molecular tools to investigate the mechanism of action of hit compounds for Acinetobacter baumannii
  Speaker: Nicole Cardoso, University of Cape Town, Cape Town, South Africa.

Continental Breakfast

Session 5: The Role of Diagnostics in Tackling AMR

• 8–8:30 a.m. | Early Development Perspective
  Speaker: Gyorgy Abel, Lahey Hospital & Medical Center, U.S.


• 8:30–9 a.m. | The Role of Diagnostics in Antimicrobial Use Clinical Development
  Speaker: Romney Humphries, Vanderbilt University Medical Center, U.S.


• 9–9:30 a.m. | Perspective From Another Oncology and How This Could Be Leveraged in the AMR Space
  Speaker: Joshua Lang, University of Wisconsin, Department of Medicine, U.S.


• 9:30–10 a.m. | Session 5 Panel Discussion and Wrap-Up.

Coffee Break

Keynote: Future in AMR Space

Closing Remarks: ASM-ESCMID Program Committee Co-Chairs